Dapagliflozin: SGLT2 inhibitor among antidiabetic drugs and its clinical application

First paragraph: content overview
Dapagliflozin is aSGLT2 inhibitorsAntidiabetic drugs lower blood sugar by inhibiting the reabsorption of glucose by the kidneys. Its main functions includeImprove blood sugar control in people with type 2 diabetes, weight loss and potential cardiovascular protection. The secondary content covers its pharmacological mechanism, applicable groups, common side effects and manufacturers. The core advantage lies in its non-insulin-dependent hypoglycemic pathway and is suitable for use in combination with other hypoglycemic drugs.

Paragraph 2: Pharmacological mechanism and core functions
Dapagliflozin selectively inhibits renal proximal tubuleSGLT-2 transporter, prevents glucose reabsorption and promotes the excretion of excess sugar through urine. According to a study in the New England Journal of Medicine, this mechanism can increase patients' average daily urinary sugar volume by 50-80 grams and significantly reduce fasting and postprandial blood sugar. Its unique feature is that it does not rely on insulin function and has a weight-loss effect on obese diabetic patients (average weight loss of 2-3kg/year).

Paragraph 3: Clinical advantages and applicable scenarios
In addition to glucose lowering, large clinical trialsDECLARE-TIMI 58It has been shown that dapagliflozin can reduce the risk of heart failure hospitalization by 27% (data shown in the table below). It is suitable for: 1) patients with type 2 diabetes who have failed single drug treatment; 2) people with high cardiovascular risk; 3) patients who need to take into account weight management. It should be noted that it may increase the risk of genitourinary system infection. It is recommended to drink no less than 1.5L of water per day during medication.

Paragraph 4: Product information and usage precautions
Domestic marketed products include AstraZeneca’sAnda Tang®(Common name: dapagliflozin tablets), the specifications are mostly 10mg/tablet. Renal function needs to be monitored during medication (eGFR<45 should be used with caution), and a common side effect is urinary tract infection (incidence of 8.4% in women vs. 5.7% in placebo). Avoid using it in combination with diuretics to prevent dehydration. False positive urine glucose tests may occur during medication.

Paragraph 5: Summary and Outlook
As a new oral hypoglycemic drug, dapagliflozin's "sugar elimination" mechanism opens up a new path for diabetes treatment. While achieving blood sugar control, the protective effect on the heart and kidneys makes it an important choice for comprehensive management. In the future, as more evidence-based medical evidence accumulates, its value in the field of metabolic syndrome treatment will be further highlighted.

Quote sources:
1. "New England Journal of Medicine" 2019 Special Review of SGLT2 Inhibitors
2. DECLARE-TIMI 58 clinical trial report (first author: Stephen D. Wiviott)
3. State Food and Drug Administration Drug Database (Approval Number: J20170040)
4. Manufacturer: AstraZeneca Pharmaceutical Co., Ltd. (Product name: Andatang®)